Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab plus AVD for Classic Hodgkin Lymphoma

被引：0
|
作者：
Kuczmarski, Thomas M. [1 ]
Ujjani, Chaitra S. [2 ,3 ]
Poh, Christina [4 ]
Warren, Edus H. [1 ]
Smith, Stephen D. [1 ,4 ]
Shadman, Mazyar [4 ]
Till, Brian G. [5 ]
Raghunathan, Vikram [1 ]
Tseng, Yolanda [4 ,6 ]
Du, Hongyan [4 ]
Vandermeer, Jacquelin [4 ]
Kelly, Alyssa [4 ]
Rasmussen, Heather [4 ]
Voutsinas, Jenna M. [7 ]
Gopal, Ajay K. [8 ]
Lynch, Ryan C. [4 ]
机构：
[1] Univ Washington, Div Hematol & Oncol, Seattle, WA USA
[2] Univ Washington, Fred Hutch Canc Ctr, Clin Res Div, Seattle, WA USA
[3] Univ Washington, Div Oncol, Seattle, WA USA
[4] Fred Hutchinson Canc Ctr, Seattle, WA USA
[5] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA
[6] Univ Washington, Fred Hutch Canc Ctr, Dept Radiat Oncol, Seattle, WA 98195 USA
[7] Fred Hutchinson Canc Ctr, Clin Res Div, Seattle, WA USA
[8] Univ Washington, Seattle, WA USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-208412
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1667 / 1668
页数：2
相关论文
共 50 条
  • [1] Extended Follow up and Immune Alterations in Patients with Classic Hodgkin Lymphoma (cHL) Treated with Frontline Single Agent Pembrolizumab Followed By AVD Chemotherapy
    Allen, Pamela B.
    Bazzi, Latifa
    Zhang, Bin
    Chen, Qing
    Slonim, Liron Barnea
    Savas, Hatice
    Advani, Ranjana H.
    Evens, Andrew M.
    Pro, Barbara
    Karmali, Reem
    Mou, Eric
    Eisner, Robert
    Bayer, Robert
    Gordon, Leo I.
    Winter, Jane N.
    BLOOD, 2024, 144 : 1664 - 1665
  • [2] Retrospective study evaluating immune-related adverse events in cancer patients treated with pembrolizumab
    Mashni, Ola K.
    Baba, Dima W.
    Mahmoud, Aseel N.
    Qur'an, Tasnim O.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (03) : 577 - 581
  • [3] EARLY UNFAVORABLE CLASSIC HODGKIN LYMPHOMA TREATED WITH A plus AVD IN A PEDIATRIC PATIENT
    Odetola, Olayinka
    McCall, David
    Gibson, Amber
    Nunez, Cesar
    Cuglievan, Branko
    Garcia, Miriam
    Roth, Micheal
    PEDIATRIC BLOOD & CANCER, 2023, 70 : S78 - S79
  • [4] Delayed immune-related adverse events in patients with advanced melanoma treated with immune checkpoint inhibitors
    Angeles, Arkhjamil
    Sonke, Eric
    Thao Phuong Nguyen
    Bahl, Gaurav
    Poon, Vincent Isaac
    Bernstein, Vanessa
    Weppler, Alison Margaret
    Savage, Kerry J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Incidence and outcomes of immune-related adverse events after immune checkpoint inhibitors in patients with Hodgkin lymphoma
    Lin, Cindy
    Tse, William W.
    Wang, Jiasheng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Immune-related adverse events: pembrolizumab ± influenza vaccine
    Reactions Weekly, 2020, 1795 (1) : 8 - 8
  • [7] Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab plus AVD in Untreated Classic Hodgkin Lymphoma
    Kuczmarski, Thomas M.
    Ujjani, Chaitra S.
    Poh, Christina
    Warren, Edus H.
    Smith, Stephen D.
    Shadman, Mazyar
    Till, Brian G.
    Raghunathan, Vikram
    Tseng, Yolanda D.
    Du, Hongyan
    Vandermeer, Jacquelin
    Kelly, Alyssa
    Rasmussen, Heather
    Voutsinas, Jenna M.
    Gopal, Ajay K.
    Lynch, Ryan C.
    BLOOD, 2024, 144 : 1666 - 1667
  • [8] Onset, duration, and clinical impact of immune-related adverse events in Hodgkin lymphoma
    Higgins, Alexandra
    Richter, Michael D.
    Patel, Shruti
    McCullough, Kristen Beth
    Habermann, Thomas Matthew
    Ansell, Stephen M.
    Thompson, Carrie A.
    Bennani, Nabila Nora
    Thanarajasingam, Uma
    Thanarajasingam, Gita
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [9] ASSOCIATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS AND SURVIVAL OF PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA TREATED WITH PEMBROLIZUMAB
    Nakamura, Kazutaka
    Toshio, Takagi
    Nemoto, Yuki
    Ishiyama, Yudai
    Ishihara, Hiroki
    Tachibana, Hidekazu
    Fukuda, Hironori
    Shinmura, Hiroaki
    Hashimoto, Yasunobu
    Kondo, Tsunenori
    Yoshida, Kazuhiko
    Iizuka, Junpei
    Ishida, Hideki
    Tanabe, Kazunari
    JOURNAL OF UROLOGY, 2022, 207 (05): : E28 - E28
  • [10] Incidence of thyroid immune-related adverse events in melanoma patients treated with pembrolizumab in an expanded access program
    Jeroen, de Filette
    Yanina, Jansen
    Max, Schreuer
    Hendrik, Everaert
    Brigitte, Velkeniers
    Bart, Neyns
    Bert, Bravenboer
    ACTA CLINICA BELGICA, 2016, 71 : 19 - 19
12345